Rohith S. Voora

Rohith S. Voora

Auto-generated profile, based on publicly available information

Rohith S. Voora

University of California San Diego School of Medicine La Jolla California USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2022 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
EQEdmund M. Qiao
Edmund M. Qiao
KGKripa Guram
Kripa Guram
NKNikhil V. Kotha
Nikhil V. Kotha
RVRohith S. Voora
Rohith S. Voora
AQAlexander S. Qian
Alexander S. Qian
BRBrent S. Rose
Brent S. Rose
Importance: Primary care physicians (PCPs) are significant contributors of early cancer detection, yet few studies have investigated whether consistent primary care translates to improved downstream outcomes.Objective: To evaluate the association of prediagnostic primary care use with metastatic disease at diagnosis and cancer-specific mortality (CSM).Design, Setting, and Participants: This cohort study used databases with primary care and referral linkage from multiple Veterans’ Affairs centers from 2004 to 2017 and had a 68-month median follow-up. Analysis was completed between July 2021 and September 2022. Participants included veterans older than 39 years who had been diagnosed with 1 of 12 cancers. Inclusion criteria included known clinical staging, survival follow-up, cause of death, and receiving care at the Veterans Affairs health system (VA).Exposures: Prediagnostic PCP use, measured in the 5 years prior to diagnosis. PCP visits were binned into none (0 visits), some (1-4 visits), and annual (5 visits).Main Outcomes and Measures: Metastatic disease at diagnosis, cancer-specific mortality (CSM) for entire cohort and stratified by tumor subtype.Results: Among 245 425 patients representing 12 tumor subtypes, mean age was 65.8 (9.3) years, and the cohort skewed male (97.6%), and White (76.1%), with higher levels of comorbidity (58.6% with Charlson Comorbidity Index scores ≥2). Compared with no prior visit, some PCP use was associated with 26% decreased odds of metastatic disease at diagnosis (odds ratio [OR], 0.74; 95% CI, 0.71-0.76; P < .001) and 12% reduced risk of CSM (subdistribution hazard ratio [SHR], 0.88; 95% CI, 0.86-0.89; P < .001). Annual PCP use was associated with 39% decreased odds of metastatic disease (OR, 0.61; 95% CI, 0.59-0.63; P < .001) and 21% reduced risk of CSM (SHR, 0.79; 95% CI, 0.77-0.81; P < .001). Among tumor subtypes, prostate cancer had the largest effect size for prior PCP use on metastatic disease at diagnosis (OR for annual use, 0.32; 95% CI, 0.30-0.35; P < .001) and CSM (SHRfor annual use, 0.51; 95% CI, 0.48-0.55; P < .001).Conclusions and Relevance: In this cohort study, increased primary care use before cancer diagnosis was associated with significant decreases in metastatic disease at diagnosis and cancer-related death, with potentially the greatest difference from annual use. PCPs play a vital role in cancer prevention, and additional resources should be allocated to assist these physicians.

7 September 2021 in Head & Neck
Verified
Journal Article
Closed access
PDF file
RVRohith S. Voora
Rohith S. Voora
JSJoshua A. Stramiello
Joshua A. Stramiello
WSWhitney A. Sumner
Whitney A. Sumner
AFAndrey Finegersh
Andrey Finegersh
AMAmir Mohammadzadeh
Amir Mohammadzadeh
RORyan K. Orosco
Ryan K. Orosco

2 April 2021 in Cancer
Verified
Journal Article
Closed access
PDF file
RVRohith S. Voora
Rohith S. Voora
NKNikhil V. Kotha
Nikhil V. Kotha
AKAbhishek Kumar
Abhishek Kumar
EQEdmund M. Qiao
Edmund M. Qiao
AQAlexander S. Qian
Alexander S. Qian
RORyan K. Orosco
Ryan K. Orosco

19 January 2023 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Closed access
RVRohith S. Voora
Rohith S. Voora
BPBharat Panuganti
Bharat Panuganti
JCJoseph A. Califano
Joseph A. Califano
CCCharles Coffey
Charles Coffey
TGTheresa Guo
Theresa Guo

24 November 2021 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
AQAlexander S. Qian
Alexander S. Qian
EQEdmund M. Qiao
Edmund M. Qiao
VNVinit Nalawade
Vinit Nalawade
RVRohith S. Voora
Rohith S. Voora
NKNikhil V. Kotha
Nikhil V. Kotha
JMJames D. Murphy
James D. Murphy
Purpose: Cancer patients frequently utilize the emergency department (ED) for a variety of diagnoses both related to and unrelated to their cancer, yet ED outcomes for cancer patients are not well documented. This study sought to define risks and identify predictors for inpatient admission and hospital mortality among cancer patients presenting to the ED.Patients and Methods: We utilized the National Emergency Department Sample to identify patients with and without a diagnosis of cancer presenting to the ED between January 2016 and December 2018. We used multivariable mixed‐effects logistic regression models to assess the influence of cancer on outcomes of hospital admission after the ED visit and hospital mortality for the whole patient cohort and individual presenting diagnoses.Results: There were 340 million weighted ED visits, of which 8.3 million (2.3%) were associated with a cancer diagnosis. Compared to non‐cancer patients, patients with cancer had an increased risk of inpatient admission (64.7% vs. 14.8%; p < 0.0001) and hospital mortality (4.6% vs. 0.5%; p < 0.0001). For each of the top 15 presenting diagnoses, cancer patients had increased risks of hospitalization (odds ratio [OR] range 2.0–13.2) or death (OR range 2.1–14.4). Although our dataset does not contain reliable estimation of stage, cancer site was the most robust individual predictor associated with the risk of hospitalization or death compared to other clinical or system‐related factors.Conclusions: Cancer patients in the ED have high risks for hospital admission and death when compared to patients without cancer. Cancer patients represent a distinct population and may benefit from cancer‐specific risk stratification or focused interventions to improve outcomes.

7 June 2022 in JCO Clinical Cancer Informatics
Verified
Journal Article
Closed access
EQEdmund M. Qiao
Edmund M. Qiao
AQAlexander S. Qian
Alexander S. Qian
VNVinit Nalawade
Vinit Nalawade
RVRohith S. Voora
Rohith S. Voora
NKNikhil V. Kotha
Nikhil V. Kotha
JMJames D. Murphy
James D. Murphy
PURPOSE: Older hospitalized cancer patients face high risks of hospital mortality. Improved risk stratification could help identify high-risk patients who may benefit from future interventions, although we lack validated tools to predict in-hospital mortality for patients with cancer. We evaluated the ability of a high-dimensional machine learning prediction model to predict inpatient mortality and compared the performance of this model to existing prediction indices. METHODS: We identified patients with cancer older than 75 years from the National Emergency Department Sample between 2016 and 2018. We constructed a high-dimensional predictive model called Cancer Frailty Assessment Tool (cFAST), which used an extreme gradient boosting algorithm to predict in-hospital mortality. cFAST model inputs included patient demographic, hospital variables, and diagnosis codes. Model performance was assessed with an area under the curve (AUC) from receiver operating characteristic curves, with an AUC of 1.0 indicating perfect prediction. We compared model performance to existing indices including the Modified 5-Item Frailty Index, Charlson comorbidity index, and Hospital Frailty Risk Score. RESULTS: We identified 2,723,330 weighted emergency department visits among older patients with cancer, of whom 144,653 (5.3%) died in the hospital. Our cFAST model included 240 features and demonstrated an AUC of 0.92. Comparator models including the Modified 5-Item Frailty Index, Charlson comorbidity index, and Hospital Frailty Risk Score achieved AUCs of 0.58, 0.62, and 0.71, respectively. Predictive features of the cFAST model included acute conditions (respiratory failure and shock), chronic conditions (lipidemia and hypertension), patient demographics (age and sex), and cancer and treatment characteristics (metastasis and palliative care). CONCLUSION: High-dimensional machine learning models enabled accurate prediction of in-hospital mortality among older patients with cancer, outperforming existing prediction indices. These models show promise in identifying patients at risk of severe adverse outcomes, although additional validation and research studying clinical implementation of these tools is needed.